Abstract:Reputed as a significant metabolic disorder, non-alcoholic fatty liver disease (NAFLD) is characterized by high fat deposits in the liver and causes substantial economic challenges to any country's workforce. Previous studies have indicated that some lactic acid bacteria may effectively prevent or treat NAFLD. In our previous study, L. acidophilus KLDS1.0901 could prevent chronic alcoholic liver injury and type 2 diabetes in mice by protecting the intestinal barrier and regulating gut microbiota. Thus, we hypothesized that L. acidophilus KLDS1.0901 would possess the ability to alleviate NAFLD. This study aimed to assess the protective effects of L. acidophilus KLDS1.0901 on high-fat diet(HFD)-induced NAFLD. Firstly, hepatic lipid profile and histological alterations were determined to study whether L. acidophilus KLDS1.0901 could ameliorate NAFLD. Then, the intestinal permeability and gut barrier were explored. Finally, gut microbiota was analyzed to elucidate the mechanism from the insights of the gut-liver axis. The results showed that Lactobacillus KLDS1.0901 administration significantly decreased body weight, Lee's index body, fat rate and liver index. L. acidophilus KLDS1.0901 administration significantly improved lipid profiles by decreasing the hepatic levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) and increasing the high-density lipoprotein cholesterol (HDL-C) levels. A conspicuous decrease of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum was observed after L. acidophilus KLDS1.0901 administration. Meanwhile, the H&E and Oil Red O-stained staining showed that L. acidophilus KLDS1.0901 significantly reduced liver lipid accumulation of HFD-fed mice by decreasing the NAS score and lipid area per total area. Our results showed that L. acidophilus KLDS1.0901 administration decreased the interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) concentrations accompanied by the increase of interleukin-10 (IL-10). L. acidophilus KLDS1.0901 administration improves the intestinal barrier function by up-regulating the mRNA levels of Occludin. Claudin-1, ZO-1 and Muc-2, coupled to the decreases of the concentration of LPS and D-lactic acid. Notably, L. acidophilus KLDS1.0901 administration modulated the gut microbiota to near normal pattern. Hence, our results suggested that L. acidophilus KLDS1.0901 can be used as a candidate to ameliorate NAFLD.

Protective Effects of Lactobacillus Acidophilus NX2-6 Against Oleic Acid-Induced Steatosis, Mitochondrial Dysfunction, Endoplasmic Reticulum Stress and Inflammatory Responses

Regulatory Mechanisms of Energy Metabolism and Inflammation in Oleic Acid-Treated HepG2 Cells from Lactobacillus Acidophilus NX2-6 Extract.

Lactobacillus Casei YRL577 Combined with Plant Extracts Reduce Markers of Non-Alcoholic Fatty Liver Disease in Mice

Lactobacillus Casei Yrl577 Ameliorates Markers Of Non-Alcoholic Fatty Liver And Alters Expression Of Genes Within The Intestinal Bile Acid Pathway

Pu'er Raw Tea Extract Alleviates Lipid Deposition in Both LO2 Cells and Caenorhabditis Elegans

(-)-Hydroxycitric Acid Alleviates Oleic Acid-Induced Steatosis, Oxidative Stress, and Inflammation in Primary Chicken Hepatocytes by Regulating AMP-Activated Protein Kinase-Mediated Reactive Oxygen Species Levels

Assessing the in vivo ameliorative effects of Lactobacillus acidophilus KLDS1.0901 for induced non-alcoholic fatty liver disease treatment

Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis.

Effects of Fatty Acid-Ethanol Amine (FA-EA) Derivatives on Lipid Accumulation and Inflammation.

Oleic Acid Protects Saturated Fatty Acid Mediated Lipotoxicity in Hepatocytes and Rat of Non-Alcoholic Steatohepatitis.

Lactobacillus Casei -fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model

Celastrus orbiculatus Thunb. extracts and celastrol alleviate NAFLD by preserving mitochondrial function through activating the FGF21/AMPK/PGC-1α pathway

Bioactive proteins and antioxidant peptides from Litsea cubeba fruit meal: Preparation, characterization and ameliorating function on high-fat diet-induced NAFLD through regulating lipid metabolism, oxidative stress and inflammatory response

Supplementation of Lactobacillus Plantarum ATCC14917 Mitigates Non-Alcoholic Fatty Liver Disease in High-Fat-diet-fed Rats

Lactucin Ameliorates FFA-induced Steatosis in HepG2 Cells by Modulating Mitochondrial Homeostasis Through the SIRT1/PGC-1α Signaling Axis

Lactobacillus Paracasei Jlus66 Extenuate Oxidative Stress and Inflammation Via Regulation of Intestinal Flora in Rats with Non Alcoholic Fatty Liver Disease

Low dose of oleanolic acid protects against lithocholic acid-induced cholestasis in mice: potential involvement of nuclear factor-E2-related factor 2-mediated upregulation of multidrug resistance-associated proteins

Dietary supplementation of probiotic Lactobacillus modulates metabolic dysfunction-associated steatotic liver disease and intestinal barrier integrity in obesity-induced mice

Lactobacillus fermentum CQPC07 attenuates obesity, inflammation and dyslipidemia by modulating the antioxidant capacity and lipid metabolism in high-fat diet induced obese mice

Oleic Acid and Palmitic Acid from Bacteroides thetaiotaomicron and Lactobacillus johnsonii Exhibit Anti-Inflammatory and Antifungal Properties

Effects of Long-Chain and Medium-Chain Fatty Acids on Apoptosis and Oxidative Stress in Human Liver Cells with Steatosis.